Recent Security Class Actions

Brainstorm Cell Therapeutics Inc. Common Stock (NASDAQ: BCLI)

Company Name:Brainstorm Cell Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: BCLI
Class Period Start:02/18/2020
Class Period End (inclusive):09/27/2023
Filing Deadline:01/02/2024

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Brainstorm Cell downplayed the severity of the Food and Drug Administration’s refusal to file letter; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the biologics license application; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.